Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.
about
The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder.Construction of a drug safety assurance information system based on clinical genotyping.Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling.Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake InhibitorsAntidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family.Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patientsRecommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors.Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors.Pharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications.Sex differences in pharmacokinetics of antidepressants.Pharmacogenetics of drug-induced birth defects: what is known so far?Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism.Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research.Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy.Clinical applications of CYP genotyping in psychiatry.Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors.Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders.Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder.Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder.5-HT2B receptors are expressed on astrocytes from brain and in culture and are a chronic target for all five conventional 'serotonin-specific reuptake inhibitors'.The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine.Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder.
P2860
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
P2860
Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.
@en
Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.
@nl
type
label
Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.
@en
Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.
@nl
prefLabel
Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.
@en
Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.
@nl
P2093
P1476
Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.
@en
P2093
Kazushi Sawamura
Toshiyuki Someya
Yutaro Suzuki
P2888
P304
P356
10.1007/S00228-004-0792-6
P577
2004-09-03T00:00:00Z
P6179
1030885145